Valuation: Elicio Therapeutics, Inc.

Market Cap 45.99M 41.2M 38.01M 34.39M 64.31M 4.38B 65.35M 453M 181M 2.29B 173M 169M 7.26B P/E 2026 *
-0.94x
P/E 2027 * -1.04x
Enterprise Value 45.99M 41.2M 38.01M 34.39M 64.31M 4.38B 65.35M 453M 181M 2.29B 173M 169M 7.26B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
73.79%
Yield 2026 *
-
Yield 2027 * -
24/10 Elicio Therapeutics, Inc. Presents Late-Breaking Phase 2 AMPLIFY-7P Results At ESMO Congress 2026 And Announces Simultaneous Publication In Nature Medicine CI
24/09 Elicio Therapeutics, Inc. Announces New Pre-Specified Analyses from Randomized Phase 2 AMPLIFY-7P Study Of ELI-002 7P in Resected Pancreatic Ductal Adenocarcinoma CI
24/09 B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy Rating MT
21/09 Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from S&P Global BMI Index CI
20/08 Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine RE
14/08 Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
10/08 Elicio Therapeutics Announces Activation Of Investigator-Initiated Phase 1 Study Of Neoadjuvant ELI-002 7P For Pancreatic Ductal Adenocarcinoma CI
06/08 Certain Stock Options of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. CI
06/08 Certain Restricted Stock Units of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. CI
06/08 Certain Pre-Funded Warrants of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. CI
06/08 Certain Warrants of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. CI
06/08 Certain Common Stock of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. CI
07/07 Elicio Therapeutics Closes $15 Million Registered Direct Offering MT
1 day+7.65%
1 week-5.67%
Current month+0.55%
1 month-0.54%
3 months-36.68%
6 months-82.27%
Current year-77.01%
1 week 1.64
Extreme 1.64
1.96
1 month 1.44
Extreme 1.44
1.98
Current year 1.44
Extreme 1.44
16
1 year 1.44
Extreme 1.44
16
3 years 1.44
Extreme 1.44
16
5 years 1.44
Extreme 1.44
24.39
10 years 1.44
Extreme 1.44
24.39
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2018
Director of Finance/CFO 54 24/03/2025
Chief Tech/Sci/R&D Officer - 19/11/2025
Director TitleAgeSince
Director/Board Member 66 01/10/2018
Director/Board Member 54 01/06/2023
Chairman 71 01/01/2017
Date Insider Type Main position Quantity % Market Cap. Importance
31/8/26 Free

Director

21,750 0.0828%
31/8/26 Free

Director

21,750 0.0828%
31/8/26 Free

Director

21,750 0.0828%
Change 5-day change 1-year change 3-year change Capi.($)
+7.65%-5.67%-80.53%-71.41% 45.99M
+0.34%+1.12%+34.75%+61.06% 64.38B
-0.20%+2.63%+14.29%+83.54% 56.16B
+0.76%+2.22%+15.65%+107.32% 54.16B
-1.43%-1.17%+26.27%+52.86% 45.33B
-0.48%-2.80%+18.01%+117.99% 42.25B
+0.82%+1.37%+227.94%+922.41% 40.78B
+0.30%+43.57%+106.36%+90.66% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average +0.62%+5.01%+39.69%+139.77% 39.27B
Weighted average by Cap. -0.07%+3.60%+50.01%+162.13%

Financials

2026 *2027 *
Net sales - -
Net income -42.06M -37.67M -34.76M -31.45M -58.81M -4.01B -59.76M -415M -165M -2.1B -158M -154M -6.64B -52.78M -47.27M -43.61M -39.46M -73.8M -5.03B -74.99M -520M -208M -2.63B -198M -194M -8.33B
Net Debt - -
Projected Income Statement - Annual - Elicio Therapeutics, Inc.
Logo Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Employees
33
Date Price Change Volume
29/10/26 USD 1.750 -5.41% 135,951
28/10/26 USD 1.850 +1.09% 216,935
27/10/26 USD 1.830 +7.65% 342,384
26/10/26 USD 1.700 -10.53% 423,010
23/10/26 USD 1.900 -2.06% 464,094
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Elicio Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.750USD
Average target price
13.67USD
Spread / Average Target
+680.95%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Elicio Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ELTX Stock